STOCK TITAN
  1. Home
  2. News
  3. MBCOF

MARVEL BIOSCIENCES CORP - $MBCOF STOCK NEWS

Welcome to our dedicated page for MARVEL BIOSCIENCES news (Ticker: $MBCOF), a resource for investors and traders seeking the latest updates and insights on MARVEL BIOSCIENCES stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MARVEL BIOSCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MARVEL BIOSCIENCES's position in the market.

News
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
Rhea-AI Summary
Marvel Biosciences Corp. (MBCOF) reports promising interim results from an acute study on MB-204, showing a reduction in Tau phosphorylation in the brain, a key feature in cognitive impairment and neurodegenerative diseases like Alzheimer's. The study demonstrated significant reductions in Tau phosphorylation in mice, indicating potential effectiveness for various neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
Rhea-AI Summary
Marvel Biosciences Corp. (MBCOF) reports promising interim results from its study on MB-204, a new autism treatment, showing significant improvements in social interaction and cognitive function in autism model mice. Dr. Julie Le Merrer highlights the potential of MB-204 to revolutionize autism therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.37%
Tags
none
-
News
Marvel Biosciences Announces Testing MB-204 on Autism by French University
Rhea-AI Summary
Marvel Biosciences Corp. (MBCOF) initiates testing of MB-204 in autism mouse model. The Company collaborates with iBrain Institute in France to assess drug effects on sociability and stereotypic behavior. CEO highlights the significant social impact and market potential of addressing autism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Marvel Biosciences Announces Closing of Non-Brokered Private Placement
Rhea-AI Summary
Marvel Biosciences Corp. has closed a non-brokered private placement of unsecured convertible debentures, raising Cdn.$500,000. The company intends to use the net proceeds for drug formulation, toxicology studies, and general working capital. The debentures will mature in three years and bear interest at a rate of twelve percent per annum. Holders of the debentures have the option to convert the outstanding principal amount into common shares at a conversion price of $0.12 per share. The company did not pay any commission, finder's fee, or similar payment in connection with the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
Rhea-AI Summary
Marvel Biosciences Corp. (MRVL) collaborates with Professor Emmanuel Planel of Laval University to study the acute effect of MB-204 on Tau protein phosphorylation in mice. MB-204, a novel fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline, has completed pre-clinical 4-week GLP toxicology studies and cGMP manufacturing and is Phase 1 clinical trial ready.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Marvel Biosciences Invited to Test MB-204 on Autism by French University
Rhea-AI Summary
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) announces collaboration with iBrain Institute to study effects of MB-204 in mouse models of autism. Drs. Le Merrer and Becker have identified a new pathway to potentially treat autism, showing promising results in reversing asocial behavior in mouse models. MB-204, a derivative of the FDA-approved adenosine A2a receptor antagonist, Istradefylline, could also offer new approaches to treat late-stage Alzheimer's disease and depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Rhea-AI Summary
Marvel Biosciences completes GLP studies for lead drug candidate MB-204, preparing for Phase 1 human trials
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock MBCOF logo
MARVEL BIOSCIENCES CORP

OTC:MBCOF

MBCOF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MBCOF Stock Data

4.21M
32.46M
29.85%
Biotechnology
Healthcare
Link
United States of America
Calgary